Department of Ear, Nose & Throat/Head & Neck Surgery,
Huddersfield Royal Infirmary, Lindley, Huddersfield, UK
1 Department of ENT Surgery, Darlington Memorial Hospital, Darlington, UK
Correspondence to: Dr J R Newton, Flat 12, Clarendon House, Uplands Road, Darlington DL2 7SL, UK E-mail: jnewton59{at}hotmail.com
| SUMMARY |
|---|
|
|
|---|
At one hour, all but 2 individuals still had symptoms; respiratory and oral symptoms were significantly more prevalent in the directly exposed group. At one month, only oral symptoms were significantly more prevalent. At 8-10 months, symptoms were still reported but there were no differences between the groups and clinical examinations revealed no specific abnormalities.
There was no convincing evidence of long-term physical sequelae from exposure to CS spray.
| INTRODUCTION |
|---|
|
|
|---|
Data on the safety of CS spray are scarce, and there is wide acknowledgment that further studies are required. Here we report observations in a cohort of 34 young adults simultaneously exposed to CS spray.
| THE INCIDENT |
|---|
|
|
|---|
| FOLLOW-UP |
|---|
|
|
|---|
10 individuals (7 men) stated that they had been hit directly in the face by the spray and were categorized as direct contact. The other 24 (8 men) had managed to avoid direct contact but all had experienced symptoms from the spray. Table 1 records the symptoms in the direct and indirect contact groups, with statistical comparisons. The most frequent symptoms experienced one hour after exposure were in the eyes, respiratory system and throat. 2 individuals said they had experienced a black-out. The only symptoms significantly more prevalent in the direct contact group at one hour were respiratory and oral.
|
At one month, symptoms were still frequent, but only oral symptoms were significantly more prevalent in the direct-exposure group.
At eight to ten months, all those in the cohort were reviewed by a consultant ear, nose and throat surgeon. They were questioned about symptoms, and the examination concentrated on a search for inflammatory changes in the mucous membranes of the upper respiratory tract and the eye. In addition, respiratory function tests were done by a trained nurse. On this occasion, 5 individuals reported respiratory symptoms (1 from the direct contact group, 4 from the indirect contact group); 2 had worsening of asthma, 2 had decreased exercise tolerance, and 1 complained of coughing fits after exercise. 1 had developed a rash seven months after exposure to the spray. 1 individual from the direct contact group reported ocular ulcers but these were not seen on examination at this stage. Other symptoms included intermittent paraesthesiae in the arms (1, direct contact) and aching joints and hip pains (2, indirect contact). There were no between-group significant differences in symptoms. Neither physical examination nor spirometry revealed any evidence of continuing morbidity.
| DISCUSSION |
|---|
|
|
|---|
Toxicology data on CS are limited, much of the research being military and some classified as secret.1 In 1969 the British Home Office concluded that whilst exposure to CS spray can be lethal in the form of toxic pulmonary damage, leading to pulmonary oedema, such an occurrence would only occur at concentrations that were several hundred times greater than exposure dosage that produces intolerable symptoms which would force the individual to leave the vicinity.2 In times of conflict such evasive action may not be possible, and in 1988 the Federal Laboratories Inc in the USA suspended sale of the agent.3 While no proven fatalities have occurred, CS spray has been implicated by the media in the death of one individual during an aggravated arrest.2
The modest amount of published work on CS spray, however, points to safety. Serious morbidity, when it has occurred, was probably due to overexposure or overuse. Even in the litigious environment of the United States, where CS spray has been used for 35 years, no damages have ever been awarded to victims.
In Britain the spray used by the police forces contains 5% CS gas, whereas in the United States it contains 1%. There are no scientific data comparing the two concentrations. In 1998 The Lancet highlighted confusion over the safety of CS spray and called for a moratorium on its use by police forces.4 The Department of Health concluded in 1999 that, although CS spray does not raise major health concerns, more research is required.5
The 34 individuals in this report were exposed to different concentrations of CS spray for similar lengths of time. Many still had symptoms one month after exposure, especially those sprayed directly, but at ten months there was little difference between the exposure groups and no ill-effects were evident on clinical examination. We conclude that, in this incident when CS was used by the police, the spray caused no long-term physical sequelae.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P.-N. Carron and B. Yersin Management of the effects of exposure to tear gas BMJ, June 19, 2009; 338(jun19_1): b2283 - b2283. [Full Text] |
||||
![]() |
B. F. Bessac, M. Sivula, C. A. von Hehn, A. I. Caceres, J. Escalera, and S.-E. Jordt Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases FASEB J, April 1, 2009; 23(4): 1102 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
R B Douglas Effects of exposure to CS J R Soc Med, August 1, 2003; 96(8): 423 - 424. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||